1. Home
  2. SPPL vs NVNO Comparison

SPPL vs NVNO Comparison

Compare SPPL & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SPPL

SIMPPLE LTD.

HOLD

Current Price

$4.60

Market Cap

19.5M

Sector

N/A

ML Signal

HOLD

Logo enVVeno Medical Corporation

NVNO

enVVeno Medical Corporation

HOLD

Current Price

$0.34

Market Cap

16.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPPL
NVNO
Founded
2016
1987
Country
Singapore
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.5M
16.7M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
SPPL
NVNO
Price
$4.60
$0.34
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
4.1K
503.6K
Earning Date
04-10-2026
10-31-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,591,508.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
24.27
N/A
52 Week Low
$2.18
$0.30
52 Week High
$16.80
$5.62

Technical Indicators

Market Signals
Indicator
SPPL
NVNO
Relative Strength Index (RSI) 47.62 36.02
Support Level $4.30 $0.30
Resistance Level $5.36 $0.37
Average True Range (ATR) 0.36 0.04
MACD 0.04 0.02
Stochastic Oscillator 46.48 32.98

Price Performance

Historical Comparison
SPPL
NVNO

About SPPL SIMPPLE LTD.

Simpple Ltd delivers an ecosystem solution that combines Internet-of-Things devices, robotic solutions, and an integrated software system operating in unison to position buildings to be future-ready. The company operates through two primary segments: the sale, warranty, and maintenance of autonomous robotic cleaning equipment (Robots), and the sale of facilities management software. The majority of its revenue is generated from the Robots segment.

About NVNO enVVeno Medical Corporation

enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.

Share on Social Networks: